Spikevax: European Medicines Agency (EMA) recommends approval of adapted COVID-19 vaccine targeting Omicron XBB.1.5
15 septembre 2023 – EMA’s human medicines committee has recommended authorising an adapted Spikevax vaccine targeting the Omicron XBB.1.5 subvariant. The vaccine — known as Spikevax XBB.1.5 — will be used to prevent COVID-19 in adults and children from six months of age.
For more information, see here.